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Assessment of the Potential Risk to
Workers from Exposure to 1,3-Butadiene
by Duncan Turnbull,* Joseph V. Rodricks,* and
Susan M. Brett*
The available epidemiologic data provide equivocal evidence that 1,3-butadiene is carcinogenic in hu-
mans; someavailablestudiessuggestthatthelymphopoietic systemisatarget, butthere are inconsistencies
among studies in the types oftumors associated with 1,3-butadiene exposure, and there is no evidence of a
relationship between length of exposure and cancer risk, as one might expect if there was a true causal
relationship between 1,3-butadiene exposure and cancer risk. The available chronic animal studies, how-
ever, show an increase intumorincidenceassociated withexposuretohighconcentrationsof1,3-butadiene.
Inadditiontothegeneral uncertaintyoftherelevanceofanimaldatatohumans, thereareseveraladditional
reasons why theNational Toxicology Program's mouse study may not be appropriate for assessing possible
human risks. These include: a) the possible involvement of a species-specific tumor virus (MuLV) in the
response in mice; b) apparent differences between mice and humans in the rate of metabolism of 1,3-bu-
tadiene toreactive epoxidesthatmaybeproximatecarcinogens; c) useofhighdose levelsthatcausedexcess
early mortality; and d) exposure of animals to 1,3-butadiene for only about half their lifetime. While
recognizing the uncertainty in using the available animal data for risk assessment, we have performed
low-doseextrapolation ofthedatatoexaminetheimplications ofthedataifhumanswereassensitiveasrats
ormice to 1,3-butadiene, andtoexamine howthe predictions ofthe animal datacomparetothatobserved in
the epidemiologic studies.
With the mouse data, because the study was of less than lifetime duration, we have used the Hartley-
Sielken time-to-tumormodel topermitestimation oflifetimeriskfromthe lessthan lifetimeexposureofthe
study. With the rat data, we have used three plausible models for assessing low-dose risk: the multistage
model, the Weibull model, and the Mantel-Bryan probit model. With both the rat and mouse data, we used
information on how much 1,3-butadiene is retained by animals exposed to various concentrations of the
chemical. This improves the accuracy ofthe low-dose extrapolation. When extrapolated to low-dose levels,
mice appeartobe at greaterrisk(by afactor of5-fold to40-fold) than rats. Some ofthisdifference (afactor
3-fold to 5-fold) may be due to the faster rate ofmetabolism of1,3-butadiene to, and higher blood levels of,
epoxide derivatives in mice than in rats.
If humans, rats, and mice were at equal risk from equal average lifetime daily doses of retained
1,3-butadiene, the mouse and rat data would predict risks to occupationally exposed humans that are
statistically inconsistent at the 95% level with the results of the available human data, unless human
exposure in the past was very much lower than is believed to have been the case.
Introduction
The risk assessment of 1,3-butadiene described here
was conducted in 1986. The purpose of the assessment
was to perform anindependent quantitative risk assess-
ment of 1,3-butadiene, with full consideration and ap-
propriate evaluation ofall data available at that time, as
an alternative tothe assessments conductedbythe U.S.
Environmental Protection Agency (EPA) (1,2). Careful
attention waspaid to theimportantcomponents ofarisk
assessment that were identified by the National Re-
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search Council (3). These are a) hazard identification,
whichisthedeterminationofwhetherornotaparticular
chemicaliscausallylinked toparticularhealtheffects; b)
dose-response evaluation, which is the determination of
the relation between the magnitude ofexposure and the
probability of occurrence of the health effects in ques-
tion; c) exposure assessment, whichisthedetermination
of the extent of human exposure that is anticipated
before orafterapplicationofcontrols; andd)riskcharac-
terization, which is the description of the nature and
magnitude of human risk, including attendant
uncertainty.
Eachofthese stagesisassociatedwith some degreeof
uncertainty. Acomprehensiveriskassessmentattempts
to reduce the uncertainties at each step as much as
possible. At the same time, remaining uncertaintiesTURNBULL, RODRICKS, AND BRETT
must be clarified and described so that an accurate
picture is presented ofthe relative uncertainties in esti-
mating the risk of any particular chemical.
Most ofthe analysis presented here is based on data
available in 1986. Where new data have become avail-
able that might alterthis analysis, these arementioned,
but we have not recalculated any of the risk estimates
based on the new data.
Hazard Identification
The purpose ofhazard identification is the qualitative
determination of the range of toxic effects that a sub-
stance is capable of causing and the conditions of ex-
posure under which those effects occur. During this
stage of risk assessment, all experimental data per-
taining to the toxicity ofthe test substance are compre-
hensively and critically evaluated to assess their re-
liability in demonstrating causation between level of
exposure to the test substance and the health effect
identified. Those studies demonstrating the most re-
liable evidence ofcausation will be those considered for
use in the next step of risk assessment, dose-response
evaluation.
In the current case, the hazard of interest is the
potential to cause cancer. The threemajortypes ofdata
consideredincarcinogenichazardidentification arefrom
studiesinhumans (clinicalandepidemiologicdata), long-
term experimental animal studies, and other biological
systems, particularly genotoxicity assays (assays for
mutations and other genetic changes).
Epidemiology Studies
The EPA (2) reviewed a number of epidemiological
studies ofoccupational cohorts with potential exposure
to 1,3-butadiene. Severalofthesestudiesinvolvedfacili-
tiesthatproducednaturalrubberproductsinadditionto
syntheticstyrene-butadiene rubber(4-8). Theinterpre-
tation of such studies, with respect to the potential
associationof1,3-butadieneandhealtheffects, however,
is limited as a result ofthe likely confounding effects of
cohort exposure to a number ofother potential carcino-
gens in nonbutadiene operations. Furthermore, it is
unlikely that 1,3-butadiene was present in significant
quantities in these facilities. The two remaining studies
evaluated by EPA (2), however, involved workers at
styrene-butadiene manufacturingplantswhoseprimary
exposure was 1,3-butadiene (9,10). Sincethepublication
of the EPA assessment, an additional epidemiologic
study of a cohort of 1,3-butadiene production workers
hasbeenreported (11). Inthefollowing, wewilllimitour
analysistothelatterthree studiesthatinvolvedworkers
primarily exposed to 1,3-butadiene and in whom other
exposures were less likely to confound a potential
1,3-butadiene-cancer association.
Review ofthe three relevant epidemiologic studies of
1,3-butadiene-exposed workers indicates that in all of
the studies, mortality from all causes ofdeath combined
and from all malignant neoplasms combined was less
than would be expected, based upon national mortality
data. When one examines the results for specific cancer
sites, only one significant elevation, for lymphosarcoma
and reticulosarcoma combined, in one cohort was ob-
served when expected mortality was based upon na-
tional mortality data, but not when it was based upon
local data (12). When the cohort was broken down by
workarea, a significant excess was observed onlyinthe
routine exposure group. The lymphosarcoma and re-
ticulosarcoma cases were concentrated in short-term
workers in this exposure group, however, arguing
against a causal association.
Certain cancer sites or groupings in these studies
revealed increases above expectation which, although
not statistically significantly elevated, deserve further
attention.
In the Matanoski et al. (10,12) study, standardized
mortality ratios (SMRs) in white males that approached
or slightly exceeded expectation were those for cancers
ofthe digestive organs (SMR=98), larynx (SMR = 109),
kidney (SMR= 103), and Hodgkin's disease (SMR=
128); SMRsforall causes and forall cancerswere 78 and
83, respectively. Workers in the production area, who
may have involved relatively higher levels of 1,3-bu-
tadieneexposure, showedfewelevatedmortalityratios.
SMRs for the previously listed sites of concern were
generallylowerthanthoseforworkersintheotherwork
areas that were considered. This argues against 1,3-bu-
tadiene being a causal factor in these elevated SMRs.
When these sites of concern from the Matanoski study
werecomparedwiththestudyresultsofMeinhardtetal.
(9) and Downs et al. (11), no consistent elevations were
observed.
InoneofthetwoplantsstudiedbyMeinhardtetal. (9)
nonstatistically significant increases (based on more
thanonecase)incancerswereobservedinthelymphatic
and hematopoietic tissues combined; also lymphosar-
coma, reticulosarcoma, leukemia, and aleukemia were
observed. Theinterpretationofthemeaningofincreases
in the grouping oflymphatic and hematopoietic cancers
is difficult because oflimitations in scientific knowledge
about their individual etiologies. It is generally ac-
cepted, however, that the leukemias encompass a di-
verse group ofmalignancies with difference cell origins:
pathogenesis, age, race and sex distributions, indicated
therapies, and likely etiologies (13,14). Similarly, the
various malignant lymphomas are considered to repre-
sentdifferentbiologicalentities, with Hodgkin's disease
representing a unique pathologic process and the re-
maining (non-Hodgkin's) lymphomas falling into two
major groups, each of which is further divided into a
number of cytologic subcategories (15,16). Although
epidemiologists have often lumped the lymphohemato-
poietic tumors together, the distribution of such dis-
eases and their clinical and pathologic diversity suggest
they likely represent different etiologic entities. It is
therefore more appropriate to consider each lymphohe-
matopoietic malignancy separately when analyzing epi-
demiologic data.
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The increase in lymphosarcoma and reticulosarcoma
in this plant studied by Meinhardt et al. (9) should be
interpreted in light ofthe other available study results.
Although an increase in this diagnostic grouping was
observed in the Texaco plant studied by Downs et al.
(11), the concentration ofcases in short-termworkers in
the routine exposure group suggests 1,3-butadiene was
not the likely causal factor. The SMR forthis diagnostic
group was significantly decreased in the larger Mat-
anoski study, and only slightly increased in the other
plantstudiedbyMeinhardtetal. (notstatistically signif-
icant, based on one case). Overall, the absence of an
increase in the larger Matanoski study, the fact that
increases were generally based upon small numbers of
cases, and that increases were not reported to apply
specifically to lymphosarcoma or reticulum cell sarcoma
tends to argue against a causal association.
Upon closer examination, a causal association be-
tween 1,3-butadiene and the leukemias inplant A ofthe
Meinhardt study was not supported. Thisisbecausethe
latencyperiodwasextremelyshort (lessthan3years)in
two cases, and in the remaining cases with sufficient
latency, leukemia cell types were diverse. A similar
excess ofleukemia was not seen in the other SBR plant
studied by Meinhardt, norin Matanoski et al. (10,12). A
slight excess ofleukemia was observed in the Downs et
al. study (11), but as it was based upon only one excess
death over expectation, its significance is unclear.
Although each ofthese studies made some attempt to
categorize workers as to past 1,3-butadiene exposure,
the lack of past industrial hygiene monitoring data
makesinterpretationofsuchcategorizeddataextremely
difficult. Furthermore, in each study analysis of such
crude exposure, class data generally failed to show con-
sistent patterns thatwould suggestdose-response asso-
ciations. This general lack ofdata suggestive ofa dose-
responsive gradient for end points of concern further
limits conclusions regarding potential causality.
These three critical epidemiologic studies have been
updated, 4nd new information was presented at the
International Symposium on the Toxicology, Carcino-
genesis, and Human Health Aspects of 1,3-Butadiene
held at the National Institute ofEnvironmental Health
Sciences, Research Triangle Park, NC. This new infor-
mation does little to clarify the role of 1,3-butadiene in
carcinogenesis in humans.
Lemen et al. (17) present some preliminary informa-
tion from continued follow-up of the cohort studied by
Meinhardt et al. (9). They report greater incidences of
lymphosarcoma and reticulosarcoma and cancers ofthe
trachea, bronchus, and lung; they do not state whether
these increases in numbers were associated with in-
creases in SMRs. It will be important to evaluate this
updated information when the full data are available.
Divine (18)reported someupdatedinformation onthe
Texacostudy(11). Theoverall patternofresultswasnot
changed in the update, with an overall reduction in
expected mortality (SMR = 84), but a significantly
elevated SMR for lymphosarcoma and reticulosarcoma
(SMR = 229). This increase was associated with indi-
viduals employed less than 10 years and first hired
duringWorld War II, however. The absence ofan asso-
ciation between length of exposure and cancer risk
raises questions regarding the causal role of 1,3-bu-
tadiene exposure in the excess.
Matanoski (19) presented an update ofher studies of
workers in eight styrene-butadiene rubber manu-
facturing facilities (10,12). As in her earlier reports,
Matanoski reported reduced overall mortality (SMR =
81) among the workers. In this update, however, she
reported a significant excess of leukemia among black
productionworkers(SMR = 656)butnotwhiteworkers
(SMR = 84), and ofnon-Hodgkin lymphoma in produc-
tionworkers (combined races, SMR = 260). Incontrast
to the studies of Meinhardt et al. and Downs et al.
(9,11,17,18), no deaths increased because oflymphosar-
coma. Although this new finding does raise some con-
cern about the lymphopoietic system as a target in
humans exposed to 1,3-butadiene, the lack of a con-
sistent pattern of tumor type calls into question the
causative role of 1,3-butadiene in the reported tumor
excess.
In conclusion, the epidemiologic data show that occu-
pationalexposureto 1,3-butadieneisnotassociatedwith
an excess risk of mortality from all causes or from all
cancerscombined. Thereissomeevidenceofanexcessof
lymphopoietic neoplasms in several studies, but the
increases were in different tumor types in different
studies (lymphosarcoma in some studies, leukemia in
others) and no clear evidence was found for an associ-
ation between duration ofemployment and tumor rate.
The absence of a consistent pattern of affected tumor
types within and across studies and the absence ofpast
industrialhygiene datamake anyconclusions about cau-
sality tentative. Overall, however, the available epi-
demiologic data do not provide strong evidence of a
causative relationship between human exposure to
1,3-butadiene andelevatedcancermortalityofanytype.
NTP Mouse Bioassay
In a National Toxicology Program (NTP) sponsored
chronic bioassay, groups of50 male and female B6C3F1
mice were exposed to air containing 0 (chamber con-
trols), 625, or 1250 ppm 1,3-butadiene for 6 hr/day, 5
days/week(20). Exposureswereplanned tocontinue for
103weeks, buttheywereterminatedatweek60formale
mice and week 61 for female mice primarily because of
neoplasia contributing to rapidly declining survival.
Significantly increased numbers of neoplasms were
observed at multiple sitesin both sexes at both low and
high doses. Incidences ofthe most prevalent neoplasms
are summarized in Table 1. In addition to the lym-
phomas, cardiac hemangiosarcomas, and alveolar/
bronchiolar adenomas/carcinomas listed in Table 1,
there was an increased incidence of epithelial hyper-
plasia, papillonas, and squamous cell carcinomas in the
forestomach in 1,3-butadiene-exposed mice of both
sexes. Among females, acinar cell carcinomas of the
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Table 1. Summary of incidence of most prevalent tumors in mice exposed for 60-61 weeks to 1,3-butadiene (20).
Airborne concentration, ppma
Tumor type and site Sex 0 625 1250
Malignant lymphoma M 0/50 23/49 29/48
F 1/50 10/49 10/49
Cardiac hemangiosarcoma M 0/50 16/49 7/48
F 0/50 11/48 18/49
Alveolar/bronchiolar adenoma/carcinoma M 2/50 14/49 15/48
F 3/49 12/48 23/49
aNumber in denominator is number ofanimals examined histopathologically for the presence ofthe tumor ofinterest. All tumors listed were
significantly increased in treated groups.
mammarygland were observedinthose exposedtoboth
low and high doses, and adenosquamous carcinomas
were observed in low-dose females. The incidence of
granulosa celltumorsoftheovarywerealsoincreasedin
dosedfemales. Eachofthesetypesoftumors occurredin
mice that alsohad malignant lymphoma, cardiac heman-
giosarcoma, or alveolar/bronchiolar adenoma/carci-
nomas. On the basis ofthese results the NTP concluded
that there was clear evidence of carcinogenicity for
1,3-butadiene in male and female B6C3F1 mice.
The largest difference observed between controlmice
and mice exposed to 1,3-butadiene in the NTP study is
the incidence of malignant lymphomas among males.
There is considerable uncertainty that the same re-
sponse would occurin the general population ofhumans
with exposure to 1,3-butadiene. This is largely because
there is substantial evidence that the presence of an
endogenous murine type C retrovirus (MuLV) in the
B6C3F1 strainmouserendersituniquelysensitivetothe
development oflymphoma.
Murine leukemia viruses (MuLVs) were the first on-
cogenicmammalianvirusestobedescribed morethan30
years ago (21). The predominant MuLV-induced re-
sponse is lymphatic leukemia, which arises spon-
taneously in many mouse strains carrying MuLV. The
type of leukemia induced is most often a thymic lym-
phoma composed of relatively immature T-cells. This
type oflymphoma is particularly noteworthy since it is
associated with 1,3-butadieneexposureinB6C3F1 mice.
It is also the type of lymphoma that increases when
MuLV-carrying mice that normally have a very low
incidence ofspontaneous leukemia are exposed to other
chemicals or irradiation (21). Thus, there is substantial
evidence that the presence of MuLVs is an important
factor in the etiology of lymphoma in B6C3F1 mice
exposed to 1,3-butadiene.
In attempting toclarify the role ofMuLV in cancer in
mice exposed to 1,3-butadiene, Irons and co-workers
(22) exposed B6C3F1 mice and NIH Swiss mice, which
donotcontaintheendogenousvirus, to 1250ppm1,3-bu-
tadiene. Theynoteda60%incidenceoflymphomasinthe
B6C3F1 mice after 1 year (similar to that seen in the
NTP study), but only 14% in the NIH Swiss mice (22).
This suggests that the presence ofthe retrovirus modi-
fied quantitatively, but not qualitatively, the response
to 1,3-butadiene. The possibility that the difference in
responsemaybeduetodifferencesinpharmacokinetics,
or DNA repair capability, however, must also be
considered.
These researchers also noted thatthe lesions induced
in B6C3F1 mice were likelytobe ofT-cellorigin (similar
to the radiation-induced and spontaneous lymphomas
known to be associated with MuLV). Moreover, they
have found that these lymphoma cells demonstrated
elevated amounts of MuLV envelope antigens. When
these lymphoma cells were cloned, anincreased expres-
sion of the c-myc proto-oncogene was observed, sug-
gesting that altered regulation of this particular gene,
caused by the presence of the retrovirus, may be in-
strumentalintheinductionoflymphomainmiceexposed
to 1,3-butadiene (23).
Itthus appearsthatthe presence ofMuLVinB6C3F1
mice enhances the incidence ofmalignant lymphoma in
response to 1,3-butadiene exposure. Since humans are
not known to carry this particular virus, extrapolation
from these specific results to humans is extremely un-
certain. Although human retroviruses do exist (HTLV
1-4), they are found in only a small proportion of the
population, and it is not known if their presence in
humans would affect susceptibility to lymphoma (or
other neoplasm) in the same way as the murine retro-
virusappearstoaffectdevelopmentoflymphomainmice
exposed to 1,3-butadiene. When using data from this
study for ariskassessment, therefore, amuch stronger
case can be made forrelying on the incidence oftumors
other than lymphoma (which presumably develop inde-
pendentlyoftheMuLVandsolelyasaresultofexposure
to 1,3-butadiene) in making interspecies extrapolations
between mice and humans.
As noted in the section on metabolism and phar-
macokinetics of 1,3-butadiene, there is some evidence
thatthe metabolism of1,3-butadiene in mice occurs at a
faster rate and results in a greater amount of toxic
metabolites than it does in rats (24,25). There is also
limited evidence suggesting the rate and extent ofme-
tabolism of 1,3-butadiene to a putative toxic metabolite
3,4-epoxybuteneinhumansismoresimilartothatofrats
than mice, although this remains to be more rigorously
demonstrated (25). In anycase, itis clearthatthere are
interspeciesdifferences intherateanddegreeofmetab-
olism of1,3-butadiene that most likely contribute to the
interspecies differences in susceptibility to its carcino-
genic effect.
Until the pharmacokinetics of 1,3-butadiene in hu-
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mans, rats, andmice are morethoroughlyunderstood, it
can be recognized only that interspecies differences in
metabolism maycontributetointerspeciesdifferencesin
susceptibility to 1,3-butadiene induced cancer. Also
mice, specifically, may be more susceptible than other
species, including humans, because of their enhanced
metabolism. Uncertainties regarding specific species
differences in metabolism of 1,3-butadiene will contrib-
ute substantial uncertainty to the extrapolation of ex-
perimental results in either mice or rats to humans and
to a quantitative risk assessment in general.
Hazleton Laboratories Europe Ltd. Rat
Bioassay
Inthisstudy, sponsoredbytheInternationalInstitute
ofSynthetic RubberProducers, Inc. (IISRP), Sprague-
Dawley rats were exposed to air containing 0, 1000, or
8000 ppm 1,3-butadiene 6 hr/day, 5 days/week (26). The
highest dose level used was limited by the explosive
nature of higher concentrations of 1,3-butadiene. Ex-
posurescontinued for111 weeksformalesand 105weeks
for females. Among females, significantly increased in-
cidences ofbenign mammary tumors, thyroid follicular
adenomas/carcinomas and uterine/cervical stromal sar-
comas, and an almost significant (p = 0.055) increase in
Zymbal gland tumors occurred in exposed animals, as
illustrated in Table 2. Among males, significantly in-
creased incidences of Leydig cell adenomas/carcinomas
and pancreatic exocrine adenomas/adenocarcinomas oc-
curred inexposed animals, also as illustrated inTable2.
In addition, there was aslight nonsignificant increase in
Zymbal gland adenomas/carcinomas in the males.
It should be noted that the results summarized in
Table 2 are substantially different from the EPA's re-
sults that were used in the derivation of a unit cancer
risk (UCR) for 1,3-butadiene based on these data (2).
The results in Table 2 were derived from review ofthe
entire final report of the 1,3-butadiene carcinogenicity
bioassay in rats that was conducted by Hazleton Labo-
ratories Europe Ltd. The reasons for the discrepancies
betweentheresultsshowninTable2andthosereported
by EPAis unknown. In ourreview ofthe conduct ofthe
study, as represented in the final report, we could find
no reason to exclude these results from consideration,
which was suggested by the EPA (2).
Itshouldbekeptinmind, however, thatthere arestill
considerableuncertaintiesinvolved inassumingthatthe
response of rats to 1,3-butadiene is predictive of the
human response.
Based onthe results ofthe Hazletonratbioassay, itis
clear that inhalation of 1,3-butadiene is carcinogenic in
rats. As discussed earlier, there is also evidence sug-
gesting that 1,3-butadiene itselfis not carcinogenic but
that its metabolites, which are reactive epoxides, are.
Therefore, there is the stronglikelihood that carcinoge-
nicity is dependent on the rate and degree to which
1,3-butadiene is metabolized. Only one study has com-
pared the human metabolism of1,3-butadiene with rats
and mice (25). In that study, liver homogenates from a
single human sample were shown to generate the same
amount ofepoxybutene asdidratliverhomogenatesand
substantially less than that generated by mouse liver
homogenates.
Table 2. Tumors in rats following inhalation exposure to 1,3-butadiene (26).
Exposure level, ppm
Tumor type and site 0 1000 8000
Females
Numbers of rats with
Mammary fibroadenoma* 40 75 67
Thyroid follicular adenoma/carcinoma* 0 4 11
Uterine/cervical stromal sarcoma* 1 5 7
Zymbal gland squamous carcinomat 0 0 4
Total number of tumor-bearing animals having any of the tumors above except
mammary fibroadenomasa 1/94 8/95 21/92
Total number oftumor-bearing animals having any of the significantly increased
tumors above including mammary flbroadenomasb 41/99 77/97 72/96
Males
Numbers of rats with
Leydig cell adenomalcarcinoma* 0 3 8
Pancreatic exocrine adenoma/adenocarcinoma* 3 1 11
Zymbal gland adenoma/carcinoma 1 1 2
Total number oftumor-bearing animals having any ofthe above tumorsc 4/96 4/96d 20/87d
*Significant differences between control and high exposure group by Fisher's exact test.
tNearly significant difference (p = 0.055).
aNumber in denominator is number of survivors at time of first tumor; uterine/cervical stromal sarcoma at 62 weeks.
bNumber in denominator is number of survivors at time offirst tumor; mammary fibroadenoma at 56 weeks.
cNumber in denominator is number of survivors at time of first tumor; Zymbal gland adenoma at 66 weeks.
dOnelow-doseanimalhadbothapancreaticexocrineadenomaandaLeydigcelltumor, and onehigh-doseanimalhadbothaZymbalglandtumor
and a Leydig cell tumor.
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Genotoxicity of 1,3-Butadiene
Studies on the genotoxicity of 1,3-butadiene have
indicated that 1,3-butadiene itself is not mutagenic in
bacteria (27,28). Both of its putative metabolites,
3,4-epoxybutene and 1,2:3,4-diepoxybutane, however,
are (29-32). Inaddition, 1,2:3,4-diepoxybutane hasbeen
shown to be mutagenic in fungi (33-35). Other evidence
thatthese twometabolites aregenotoxicinclude studies
demonstratingtheabilityof3,4-epoxybutene toalkylate
DNA in vitro (36) and to induce sister chromatid ex-
changes (J. W. Allen, unpublished data). These studies
also demonstrate that 1,2:3,4-diepoxybutane induces
chromosomal aberrations and sister chromatid ex-
changes in vivo (37) and in cultured mammalian cells
(38,39). 1,2:3,4-Diepoxybutane also increases the inci-
dence of sex-linked recessive lethal mutations and
broken chromosomes in Drosophila (40-42).
These experimental data are notdirectlyapplicable to
aquantitative risk assessment. These results, however,
are important in both the overall assessment of the
carcinogenicity of a compound in the hazard identifica-
tion step and intheinterspecies and low-dose extrapola-
tion ofthe dose-response evaluation step ofrisk assess-
ment. Forexample, thereis much currentevidence that
many known carcinogens are mutagens and that they
can interact and cause damage to DNA. Thus, evidence
that a chemical or its metabolites are mutagens and/or
thattheyinteract or causedamagetoDNAisconsidered
to be supportive evidence that it is a carcinogen. At the
sametime, evidencethat ametabolite alone causesthese
effects suggests that metabolism is crucially important
in the manifestation of any carcinogenic effect of the
chemical and emphasizes the importance ofconsidering
metabolic similarities and differences in making inter-
species extrapolations. Additionally, evidence that the
metabolites of a compound are likely to be responsible
for anycarcinogenic effectemphasizes thedesirabilityof
basing a low-dose extrapolation of the dose-response
curve onthe effectivedosesofthetoxicmetaboliteatthe
target site (which may be substantially different in
different species) than on the administered dose of the
parent compound.
Strength of the Evidence of Carcinogenicity
The scientific datadescribed above attest tothe carci-
nogenicity of 1,3-butadiene in rats and mice. They also
demonstrate the strong likelihood that a metabolite (or
metabolites) of1,3-butadiene isprobablyresponsible for
its carcinogenicity. This is based on the fact that mice
appear to be especially susceptible to the carcinogenic
effect of 1,3-butadiene, that they also produce more
metabolites at a faster rate than rats do, and that both
the metabolites 3,4-epoxybutene and 1,2:3,4-diepoxy-
butane are directly mutagenic whereas 1,3-butadiene is
not. This emphasizes the importance of interspecies
differences in metabolism in assessing susceptibility to
1,3-butadiene carcinogenicity.
The epidemiological evidence is much less clear. The
data available when this analysis was originally con-
ducted did not support a causal association between
1,3-butadiene exposure and increased mortality from
any specific cancer type. More recent data are more
supportive of a causal association, but inconsistencies
between studies in types of neoplasms affected and a
lack of evidence of a dose-response relationship render
the epidemiologic data inconclusive. However, to com-
pare the results obtained in the animal studies with the
results ofthe epidemiologic studies, we have performed
low-dose extrapolation ofthe experimental animaldata.
Metabolism and Pharmacokinetics of
1,3-Butadiene
Although the inhalation of1,3-butadiene induced can-
cer in both rats and mice, the mice showed a much
greater incidence of tumors at substantially lower ex-
posure levels than rats. This suggests either that mice
were much more sensitive to the carcinogenic effects of
1,3-butadiene or that differences in one or more phar-
macokinetic parameters (e.g., absorption, distribution,
metabolism, elimination) existedbetweenthesespecies.
The demonstration ofsuch interspecies differences em-
phasizes the possibility that there may also be inter-
speciesdifferencesbetweenrodents andhumansintheir
response to 1,3-butadiene as a result of differences in
pharmacokinetics and other biological factors.
Initial work on the metabolism of 1,3-butadiene was
carried out by Malvoisin et al. (43) usingratliver micro-
somes. These authors incubated rat liver microsomes
with 1,3-butadiene and found that it was metabolized to
3,4-epoxybutene (butadiene monoxide). They further
demonstrated that induction ofmicrosomal enzymes by
pretreatment with phenobarbital enhanced conversion
to 3,4-epoxybutene and that microsomal monooxygen-
ase wasthe enzyme responsible. In asubsequentreport
these researchers compared the in vitro activity ofthe
P-450 monooxygenase enzyme responsible for con-
verting 1,3-butadiene to 3,4-epoxybutene, to the activ-
ity ofthe epoxide hydrolase enzyme, which they found
reduced the epoxide to a putatively less toxic metabo-
lite, 3-butene-1,2-diol (44). They found the monooxy-
genase to be about five times more active than the
hydrolase. They, therefore, suggested that the pu-
tatively toxic butadiene monoxide would be formed
moreefficientlyandrapidlythantheputativelynontoxic
butene diol.
In the most recent report in this series of inves-
tigations, Malvoisin and Roberfroid (45) demonstrated
the in vitro conversion of 3,4-epoxybutene to both
1,2:3,4-diepoxybutane and 3,4-epoxy-1,2-butanediol in
rat liver microsomes. Microsomal monooxygenase was
responsible forboththe conversion of3-butene-1,2-diol,
formed bythe action ofepoxide hydrolase on3,4-epoxy-
butene, to 3,4-epoxy-1,2-butane diol and for the con-
versionofthe3,4-epoxybuteneto1,2:3,4-diepoxybutane.
On the basis of the appearance of these metabolites in
microsomesincubatedwith3,4-epoxybuteneandontheir
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H2C =CH-CH =CH2
(1,3-butadiene)
NADPH
42 microsomes
IF r (monooxygenase)
H2C =CH-C8ICH2 0
(3,4-epoxybutene; butadiene monoxide; vinyl oxirane)
H20 / NADPH
epoxide / 02 microsomes
hydrolase (monooxygenase)
H2C =CH-CHOH-CH20H
10\
(3-butene-1,2-diol) H2q-CH-CH-CH2
NADPH C
°2 microsomes (1,2:3,4-diepoxybutane)
(monooxygenase)
H2q-CH-CHOH-CH20H
0
(3,4-epoxybutane-1,2-diol)
FIGURE 1. Proposed scheme for the metabolism of 1,3-butadiene
based on Malvoisin and Roberfroid (46).
previous work, these authors proposed the scheme pic-
tured in Figure 1 for the metabolism of 1,3-butadiene.
Morerecentstudies(24,25,46-49)haveconfirmedthis
general pathway ofmetabolism and have demonstrated
that the metabolism of 1,3-butadiene to epoxybutene
was more rapid in mice than in rats, leading to higher
tissue levels ofthe epoxide in mice than in rats. Schmidt
and Loeser (25) also examined the ability ofhuman liver
and lungtissue homogenate (from a single individual) to
metabolize 1,3-butadiene. They found that the rate of
production ofepoxybutene inliver was similarinthe rat
and human and lower than in mouse. Additionally, no
epoxybutene was detected in human lung tissue homog-
enate exposed to 1,3-butadiene, while it was detected in
ratlunghomogenateand was5-to6-foldhigherin mouse
lunghomogenatethaninthe rat. Thesedifferences may,
at least in part, explain the differences in susceptibility
among species.
Dose-Response Evaluation
This step in a risk assessment involves two types of
extrapolation: interspecies extrapolation and low-dose
extrapolation. The result ofthese processes is the deri-
vation of a UCR that reflects the lifetime cancer risk to
humans, given exposure to oneunitofdose ofthecarcin-
ogen. There is considerable uncertaintyinvolved in each
of these extrapolations because they are not ordinarily
based on empirical data. The only data suitable for the
dose-response evaluation of 1,3-butadiene are those
from the two chronic animal bioassays. Even so, use of
eitherofthese datasetsintroducesuncertainty overand
above that which is unavoidable when relying on ex-
perimental animal data to predict human responses.
Extrapolation to humans and to low doses for each of
these data sets are described below, along with a de-
scription of the uncertainties involved.
Mouse Study
Use ofthe datafromthe NTP mouse bioassayforrisk
assessment is complicated by several factors:
* As mentioned earlier, there is evidence that an
endogenous murine retrovirus may be involved in
the development oflymphoma in the 1,3-butadiene-
exposed mice.
* There is evidence, particularly in males, of satura-
tionofthecarcinogenicresponse, sincelow-doseand
high-dose animals showed similar tumor incidence.
As a result, less information than usual is available
regarding the shape of the dose-response relation-
ship.
* The early termination ofthe study makes the stan-
dard low-dose extrapolation models, such as the
multistage model, unsuitable.
To partially address some ofthese uncertainties, sev-
eral procedures have been used:
* Separate extrapolations were conducted based on
tumor-bearing animals having any of the tumors
thatshowed asignificant increaseinincidenceinone
or both of the treated groups, and on the same
animals except those that developed lymphoma.
* To better reflect the critical target-site dose, the
retained doses ofbutadiene estimated based on stu-
dies performed for NTP and described by EPA (2)
were used as shown in Table 3; a more detailed
treatment ofthe pharmacokinetics ofbutadiene was
not considered possible.
* To permit calculation oflifetime risk from the less-
than-lifetime mouse study, the Hartley-Sielken
general product model was used:
P(t,d) = 1 - exp[-ao + cx1d1 + + akdk)
(ajTT+amTm)] where p(t,d) is the probability
(risk) ofdeveloping a tumor from exposure to
dose (d) by time (T), ao, ot . . . aO are dose-
related parameters and 13 ... 1m are time-
related parameters estimated by fitting the
experimental data on the time ofidentification
of a tumor in an animal and its daily retained
dose to the above equation.
The results of applying this model to the data from
male mice (which predict the higher risk) are shown in
Table 4 for an arbitrary lifetime daily dose of 1 mg/kg!
day. Bothmaximumlikelihood estimatesand95%upper
confidence limits on the estimates are shown for two
slightly different forms ofthe Hartley-Sielken model.
Rat Study
The Hazleton rat study (26) has fewer confounding
factors associated with it. There is, therefore, likely to
be less uncertainty associated with extrapolation to
humans than would be the case with the NTP mouse
study (20). One complicating factor in the use ofthe rat
data is the fact that there is considerable evidence that
the absorption of 1,3-butadiene in rats becomes satu-
rated at levels above about 1000 ppm (24,49). This level
ofexposure thereforerepresents alevelbeyond which a
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Table 3. Retention of 1,3-butadiene in mice exposed by inhalation [NTP data cited by EPA (2)].
Average daily dose 1,3-butadiene Exposure 1,3-Butadiene and metabolites retained and metabolites,
ppm ,Lg/L ,umole/kg mg/kg mg/kg/daya
7 13 33 1.8
80 145 120 7.1
1040 1900 660 35.7
625 25.7 18.4
1250 38.9c 27.8
aAmount retained multiplied by 5 days exposure/7 days per week since mice were exposed for only 5 days/week in the NTP study.
bEstimated by interpolation; corresponds to low dose in NTP bioassay.
cEstimated by extrapolation; corresponds to high dose in NTP bioassay.
Table 4. Maximum likelihood estimates and 95% upper-confidence limits on extra-lifetime risk-based on tumors
observed in male mice exposed to 1,3-butadiene via inhalation (20).
Estimates derived using Hartley-Sielken general product model where
P(T,d) = 1- exp{ -(o + aldl+.....Oakdk)(IlT +......**.*mTm)}
Estimate ofextra risk, 95% Upper-confidencelimitonextrarisk,
Tumors modeled mg/kg/day1 mg/kg/day-
k=2, m=2
All significantly increased
tumorsa
All significantly increased
tumorsa except malignant
lymphomas
1.8 x 10- 2.1 x 10-1
9.5 x 10-2 1.1 x 10-,
k=2, m=3
All significantly increased 1.9 x 10-1 2.2 x 10-1
tumorsa except malignant
lymphomas
aSignificantly increased tumors: malignant lymphoma, cardiac hemangiosarcoma, lungadenoma/carcinoma, forestomachpapilloma/carcinoma.
Table 5. Retention of 1,3-butadiene in rats exposed by inhalation [NTP data cited by EPA (2)].
Exposure 1,3-Butadieneandmetabolitesretained Averagedaily dose 1,3-butadiene andmetabolites,
ppm Fg/L ,imole/kg mg/kg mg/kg/daya
70 125 40 2.2
930 1700 160 8.7
7100 12800 660 39.0
1000 10.5b 7.4
8000 38.5c 27.5
aAmount retained multiplied by 5 days exposure/7 days per week since mice were exposed for only 5 days/week in the NTP study.
bEstimated by interpolation; corresponds to low dose in Hazleton study (26).
cEstimated by extrapolation; corresponds to high dose in Hazleton study (26).
proportional increase in the amount of 1,3-butadiene
absorbed would not be expected to occur. In other
words, itisveryhighlylikelythattheadministereddose
in the Hazleton rat bioassay does not proportionally
reflect either the internal or effective dose. Moreover,
estimates ofinternaldosebasedonanadministereddose
of8000 ppm as will be done for these data will be very
uncertain. Ontheotherhand, thereisclearevidence ofa
dose-response relationship in the incidence oftumors in
both male and female rats, as shown in Table 2. This
suggeststhatwiththehigheradministered dosemoreof
the toxic metabolite(s) are reaching target sites than
with the lower administered dose. This emphasizes
again that the shape ofthe dose-response curve, based
on administered doses forthese data, is veryuncertain.
To provide both a conservative estimate of possible
risk and an indication ofthe range ofuncertainty, low-
doseextrapolation wasperfornedusingall significantly
increased tumor types using the multistage model, the
model normally used by EPA, and two other plausible
models: the Weibull model (50) and the Mantel-Bryan
probit model (51). As with the mouse study, data on
retention of inhaled 1,3-butadiene from studies con-
ducted by NTP and cited by EPA (2) were used in an
attempt to improve the accuracy of the extrapolation.
ThesedataareshowninTable5, alongwithestimates of
the retained daily doses in the bioassay based on the
empiricaldata. Useofthesedata(andthecorresponding
mousedata)forriskassessmentinvolvestheassumption
that the amount of 1,3-butadiene retained at any ex-
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Table 6. Maximum likelihood estimates ofdose coefficients and maximum likelihood and 95% upper-confidence limits on extra-lifetime
risks-based on tumors observed in rats exposed to 1,3-butadiene via inhalation (26).
Estimates derived using the multistage model (GLOBAL 82) where
P(d) = 1-exp (-qo-qldl- . . . qkdk)
Maximumlikelihood estimates Maximum likelihood estimates 95% Upper-confidence limit on excess
Sex Tumors modeled ofdose coefficients ofexcessriskatdoseof1mg/kg/day risk at dose of 1 mg/kg/day
Male Significantly qo2.33 x 10-2 1.93 x 10-3 1.10 X 10-2
increased tumorsa q1 1.66 x 10-3
q2 2.78 x 10-4
Significantly
increased tumorsa
plus Zymbal gland
adenoma/carcinoma
Female Significantly
increased tumorsb
(not including
mammary fibro-
adenomas)
qo2.13 x10-2
q1 6.30 x1O-4
q22.94 x 10-4
qo 1.14 x10-2
q, 9.27x 10-3
q2 0
Significantly qo7.21 x 10-1 3.43 x 10-2 4.97 x 10-2
increased tumorsc q1 3.43 x 10-2
(including mammary
fibroadenomas)
aSignificantly increased tumors: Leydig cell adenoma/carcinoma, pancreatic exocrine adenoma/carcinoma.
bSignificantly increased tumors: thyroid follicular adenoma/carcinoma, uterine/cervical stromal sarcoma, Zymbal gland squamous carcinoma,
mammary fibroadenoma.
cPoor goodness offit of all three dose levels to multistage model: therefore, only control and low-dose groups modeled.
Table 7. Weibull and Mantel-Bryan model parameters based on tumors observed in rats exposed to 1,3-butadiene via inhalation (26).
Estimates derived using the Weibull model where:
P(d) = 1-exp (-a-bdm)
Maximum likelihood estimates Maximum likelihood estimates 95% Upper-confidence limit onexcessrisk
Sex Tumors modeled of dose coefficients ofexcessriskatdoseof1mg/kg/day at dose of 1 mg/kg/day
Male Significantly a 2.11 x 10-2
increased tumorsa b 5.43 x 10-4 5.43 x 10-4 9.48 x 10-3
plus Zymbal gland m 1.84
adenoma/carcinoma
Female Significantly a 1.15 x 10-2 9.25 x 10-3 1.27 x 10-2
increased tumorsb b 9.29 x 10-3
(not including m 1.00
mammary fibro-
adenomas)
Estimates derived using the Mantel-Bryan model where:
P(d) = PO + (1-PO) 4) (a + loglo d), 4) = standard normal distribution function
Male Significantly PO 1.64 x 10-2 8.6 x lo-3 1.5 x 10-2
increased tumorsa a -2.38
plus Zymbal gland
adenoma/carcinoma
Female Significantly PO 1.01 x 10-2
increased tumors' a -2.25 1.22 x 10-2 2.0 x 10-2
(not including
mammary fibro-
adenomas)
aSignificantly increased tumors: Leydig cell adenoma/carcinoma, pancreatic exocrine adenoma/carcinoma.
bSignificantly increased tumors: thyroid follicularadenoma/carcinoma, uterine/cervical stromal sarcoma, Zymbal glandsquamous carcinoma,
mammary fibroadenoma.
9.24 x 10-4
9.27 x 10-3
9.36 x 10-3
1.28 x 10-2
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posure concentration is not affected by repeated ex-
posure. The validity of this assumption is unknown.
The results of the low-dose extrapolation of the rat
data are shown inTables6and7forthevarious datasets
and models used.
Exposure Assessment
As noted previously, measurements of workplace
1,3-butadiene concentrations in styrene rubberfacilities
provide the best available estimates for levels ofhuman
exposure. Workplace concentrations have generally not
exceeded 10 to 20 ppm (2). Therefore, human risk to
1,3-butadiene is estimated, assuming 10 ppm. Also, in
order to provide a range of possible risks, these are
estimated, assuming 1 and 100 ppm exposure. Since
these exposures are likely to be only occupational, it is
assumed that exposure will be limited to 8 hr/day, 5
days/week, 50 weeks/year for40 years over alifetime of
70 years. An exposure to 1 ppm under this scenario is
actually equivalent to a lifetime average daily dose of
0.062 mg/kg/day (as illustrated below), assuming 50%
absorption of inhaled 1,3-butadiene.
1 ppm 1,3-butadiene = (2.2 mg 1,3-butadiene) (10 m3 air breathed/
day) (5/7 days/week) (50/52 weeks/year)
(40/70 years/lifetime) / (70 kg body weight)
= 0.062 mg/kg/day, lifetime average daily dose.
Risk Characterization
The final step in the risk assessment process (risk
characterization) involves the evaluation ofall relevant
data pertaining to the likelihood that the substance in
question is ahuman carcinogen, the quantitative results
of the low dose and interspecies extrapolations, and
information on the estimated or actual human exposure
to the carcinogen. These components ofrisk assessment
have been described in the previous sections.
Risk Estimates Based on Animal Data
Data described demonstrate that 1,3-butadiene in-
duces a variety of tumor types in mice and rats. Using
the estimates of cancer potency and the exposure sce-
nariospresented above, the lifetime riskto humans that
may exist as a result of exposure to 1,3-butadiene has
been estimated. Because several data sets, extrapola-
tion models, and levels of human exposure have been
modeled (1, 10, and 100 ppm), several estimates ofrisk
have been derived. The estimates are summarized in
Tables 8 and 9.
When applied to the female rat data, the Weibull
model gives results almost identical to those of the
multistage model, since in both cases the best-fit is a
linear curve. The male rat data give a nonlinear fit with
the Weibull model and predict maximum likelihood es-
Table 8. Estimates of extra-lifetime risk based on tumors observed in rats exposed to 1,3-butadiene.
Basis ofrisk estimate Estimated humanexposurea Multistage Weibull model Mantel-Bryan model
Maximum likelihood estimates of extra-lifetime risk.
Based on significantly 1 ppm 5.75 x 10-4 5.76 x 10-4 2.77 x 10-4
increased tumors in 10 ppm 5.75 x 10-3 5.74 x 10-3 7.07 x 10-3
female rats 100 ppm 5.75 x 10-2 5.60 x 10-2 7.30 x 10-2
Based on significantly 1 ppm 1.04 x 10-4 3.27 x 10-6 1.65 x 10-4
increased tumors in 10 ppm 1.14 x 10-3 2.25 x 10-4 4.80 x 10-3
male rats 100 ppm 2.10 x 10-2 1.54 x 10-2 5.59 x 10-2
95% Upper confidence limits on extra-lifetime risk
Based on significantly 1 ppm 7.94 x 10-4 7.93 x 10-4 5.63 x 10-4
increased tumors in 10 ppm 7.94 x 10-3 7.90 x 10-3 1.20 x 10-2
female rats 100 ppm 7.94 x 10-2 7.63 x 10-2 1.04 x 10-1
Based on significantly 1 ppm 6.82 x 10-4 5.88 x 10-4 3.70 x 10-4
increased tumors in 10 ppm 6.82 x 10-3 5.86 x 10-3 8.79 x 10-3
male rats 100 ppm 6.82 x 10-2 5.71 x 10-2 8.47 x 10-2
aOccupational exposure to 1 ppm is equivalent to an average lifetime daily dose of 0.062 mg/kg.
Table 9. Estimates of extra-lifetime risk based on tumors observed in male mice exposed to 1,3-butadiene.
Basis of risk estimate Estimated human exposurea Estimates of extra-lifetime risk
Maximum likelihood estimates ofextra-lifetime risk
Based on all significantly 1 ppm 4.65 x 10-3
increased tumors in male 10 ppm 4.56 x 10-2
mice except malignant lymphomas 100 ppm 3.73 x 10'
95% Upper confidence limits on extra-lifetime risk
Based on all significantly 1 ppm 5.50 x i03
increased tumors in male 10 ppm 5.34 x 10-2
mice except malignant lymphomas 100 ppm 4.26 x 10-1
aOccupational exposure to 1 ppm is equivalent to an average yearly daily dose of 0.109 mg/kg.
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timates of risk somewhat lower than the multistage
model (1.4-fold lowerat 100 ppm; 5-foldlowerat 10 ppm;
and 32-fold lower at 1 ppm). However, the upper 95%
confidence limit on risk forthe Weibull model, based on
the male rat data, is within 84% of the corresponding
multistage model value for all three exposure levels.
The Mantel-Bryan model predicts risks that are
within a factor ofthree ofthose predicted by the multi-
stage model at all three exposure levels, as shown in
Table 8.
Theriskestimates presented inTable 9, derived from
data on male mice, are higher by 5-fold to 40-fold than
those derived from the rat data. This difference may, in
part, be due tothe apparently higherrate ofmetabolism
of 1,3-butadiene to its monoepoxide in mice than in rats
(25).
Conflict between Risks Predicted by Animal
and Epidemiological Data
In contrast to the risk to humans predicted by use of
eitherthe mouse orratdata(asshowninTables8and9),
there is, as discussed earlier, only equivocal evidence of
an excess risk to workers who have been exposed to
1,3-butadiene.
The inconsistency of the predictions of risk made by
EPA(2)based onthe NTP mousestudyhasbeendemon-
stratedby IISRP(52), whichcalculated the extradeaths
predicted by EPA's analysis of the NTP study (20),
assuming different occupational exposure levels of
1,3-butadiene. IISRP compared those estimates to the
number of deaths due to lymphopoietic cancer in the
studybyMatanoski etal. (10). Thiscomparison is shown
inTable 10alongwith anestimate oftheprobabilitythat
the observed and predicted deaths are consistent.
It is clear that if average human exposure in the
Matanoski study cohort was greater than 1 ppm (as it is
likely to have been), the EPA estimates based on the
NTP mouse study are incompatible with the observed
response.
Similar calculations can be performed using the risk
estimates derived from the Hazleton rat data, though
the relevance is less clear because no excess of lym-
phopoietic cancers was seen in the rats (26). Using
IISRP's estimates of average length of exposure (10
years) and average length offollow-up (18 years) in the
Matanoskietal. study(10), thefollowingcalculations are
possible:
At an exposure level of1 ppm, working lifetime aver-
age exposure =
1 x 10 years x
50 years
240 days
365 days
x 8hr
24hr
= 0.044 ppm
Individual lifetime risk =
0.044ppm x 4.2 x 10-3(ppm)-
= 1.84xl0-4
where4.2 x 10-3iSthe average cancerpotencyformale
and female rats from Table 6.
Expected excess cases =
1.84 x 10- X 13920 x 18/50
= 0.923
Similarly, the expected excess cases for 5, 10, and 25
ppm exposure levels can be calculated as 4.6, 9.2, and
23.1, respectively.
Table 11 shows an analysis similar to that in Table 10,
butitisbased on ourassessmentoftheratdata. Because
the rat data predict lower risks, these data do not over-
predict as much as the mouse data do, though they still
overpredictsomewhat. Thisimprovement maypartlybe
attributed to the apparent closersimilarity betweenthe
ratandhumanthanbetweenthe mouseandhumaninthe
pharmacokinetics of 1,3-butadiene.
As noted earlier, the recent epidemiology study by
Downs et al. (11) did show a slight excess of lym-
phopoietic cancer. However, this excess is significantly
lessthanwouldbepredicted fromtheresultsofthe NTP
Table 10. Excess lymphopoietic cancer deaths predicted among study cohort
of Matanoski et al.a by EPA modeling of NTP mouse data (52).a
Assumed exposure Probability of observing
level, ppmb Extra deaths predicted Total deaths predicted 40deathsgiven EPA'spredictions
1 5.5 52.6 0.09
5 27.5 74.6 1.8 x 10-5
10 54.9 102.0 6.4 x 10-12
25 137.3 184.4 4.1 x 10-36
aAssumes all excess risk to humans is due to lymphopoietic cancer.
bBecause no good estimates of exposure level exist, the effect of assuming different levels is examined.
Table 11. Excess lymphopoietic cancer deaths predicted among study cohort
of Matanoski et al. (10) by EPA modeling Hazleton rat data (26).
Assumed exposure Probability ofobserving
level, ppm Extra deaths predicted Total deaths predicted 40deathsgiven EPA'spredictions
1 0.92 48.0 0.138
5 4.6 51.7 0.055
10 9.2 56.3 0.014
25 23.1 70.1 6.7 x 10-5
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mouse study, assuming worker exposure levels were in
the range of 10 to 20 ppm (or higher). The excess in the
Downs study is, however, numerically consistent with
the excess total risk predicted on the basis ofthe Haz-
leton rat bioassay.
The apparent consistency between the Downs et al.
study(11) andtheratdatamustbetempered bythefact
that the sites where an excess oftumors occurred inthe
rat study (Leydig cells, pancreas, thyroid, uterus/
cervix, andpossiblyZymbalgland)arenotrelatedtothe
sites apparently affected in the Downs et al. study
(lymphohematopoietic cancer). As such, the apparent
numericalconsistencyislikely coincidental, particularly
since no such increase in lymphohematopoietic cancer
was observed in the larger, statistically more powerful
study by Matanoski et al. (10,12).
We have not had the opportunity to examine how the
predictions of the animal data match the recently up-
dated epidemiologic data; such an evaluation would be
informative.
Conclusions
The available epidemiologic data provide only equiv-
ocal evidence of a carcinogenic risk from human ex-
posure to 1,3-butadiene. Inconsistencies between the
predictions ofrisk onthe basis oftheanimal studies and
humanexperience callforcautioninattemptingtoquan-
tify human risk on the basis ofthe animal data. These
inconsistencies may arise because of the probable in-
volvement ofmurine leukemiavirusinmiceandbecause
the target organs that are affected in the rats show no
sign of elevated cancer incidence in humans. Also the
possible targets in humans are not affected in rats. It is
to be hoped that both the continued follow-up of the
occupationally exposed cohorts and further research on
1,3-butadiene pharmacokinetics and its possible mech-
anism of action will improve our understanding of pos-
sible human risk from the gas.
Thework inthispaperwasperformed undercontracttothe 1,3-Bu-
tadiene Program Panel of the Chemical Manufacturers Association
(CMA), and we thank CMA for its support, particularly Robert
Romano, manager ofthe panel. We also acknowledge the important
contributions ofJan Storm, who contributed to the original report to
CMA, and to Gregory Chandler, who gave clerical support.
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